Xoma Technology Ltd.

Xoma (us) LLC

Musc Foundation for Research Development

Alector LLC

Xoma Techolology Ltd.

Xoma Corporation

Marina Roell

Linda Masat

Gang Chen

Arnold H Horwitz

Mary Haak-Frendscho

Daniel H Bedinger

Kirk William Johnson

Toshihiko Takeuchi

Amer M Mirza

Isaac J Rondon

Ou Li

Hassan Issafras

Agnes Choppin Holmes

Mark Rubinstein

Hoa Giang

Lauren Schwimmer

Kristin Camfield Lind

Llewelyn Lao

Arnon Rosenthal

Mark Leslie White

Seung-Joo Lee

Spencer Liang

John Corbin

Angie Grace Yee

Robert Bauer

The present disclosure relates, in general, to human antibodies against human interleukin 2 (IL-2) and methods of use of such antibodies for modulating IL-2 activity and use in the treatment of conditions such as cancer, autoimmune disease, or infection.

Antibodies that bind interleukin-2 and uses thereof

The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a MerTK polypeptide, e.g., a mammalian MerTK or human MerTK, and use of such compositions in treating an individual in need thereof.

Anti-MerTK antibodies and methods of use thereof

The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.

Screening methods

An IL-1&#x3b2; binding antibody or IL-1&#x3b2; binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 2, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease, and a method of preparing an affinity matured IL-1&#x3b2; binding polypeptide. IL-1&#x3b2; binding antibodies or IL-1&#x3b2; binding fragments thereof are provided which have desirable affinity and potency.

Pharmaceutical compositions comprising IL-1B binding antibodies and fragments thereof

The present disclosure relates to novel triple tag sequences that may comprise a 6&#xd7; histidine tag, a c-myc tag and a V5 tag. The present disclosure also provides polynucleotides, proteins, vectors and host cells that comprise the triple tag sequence of the present disclosure, including libraries of such polynucleotides, proteins, vectors and host cells. The novel triple tag sequences of the present disclosure may be used in phage display vectors and phage libraries and in methods for detection, screening, capture, purification, quantitation, and/or recovery of proteins of interest to which they are linked. Proteins of interest include antibodies such as single chain antibodies, single chain antibodies, and Fab fragments of antibodies or peptides such as non-antibody peptides.

Triple tag sequence and methods of use thereof

Triple tag sequences and methods of use thereof

Method of treating inflammatory eye disease with IL-1&#x3b2; binding antibodies

The present invention relates to materials and methods for human antibodies specific for the peptide hormone gastrin and uses of these antibodies in the treatment of subjects having cancer and other conditions or disorders related to gastrin expression.

Human antibodies specific for gastrin materials and methods

Method of treating an IL-1 related coronary condition

IL-1&#x3b2; binding antibodies and fragments thereof

Methods of treating or preventing an IL-1 related disease or condition in a mammal comprising administering an effective amount of an IL-1&#x3b2; binding antibody or IL-1&#x3b2; binding fragment thereof. An IL-1&#x3b2; binding antibody or IL-1&#x3b2; binding fragment thereof is provided comprising the amino acid sequence of SEQ ID NO: 15 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, and a method of preparing an affinity matured IL-1&#x3b2; binding polypeptide. IL-1&#x3b2; binding antibodies or IL-1&#x3b2; binding fragments thereof are provided which have desirable affinity and potency.

Method of treating an IL-1 related autoimmune disease or condition

Method of treating an IL-1 related cancer

An IL-1&#x3b2; binding antibody or IL-1&#x3b2; binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 26 and SEQ ID NO: 11, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1&#x3b2; binding antibodies or IL-1&#x3b2; binding fragments thereof are provided which have desirable affinity and potency.

IL-1&#x3b2; binding antibodies and binding fragments thereof

An IL-1&#x3b2; binding antibody or IL-1&#x3b2; binding fragment thereof comprising the amino acid sequence of SEQ ID NO: 8 and SEQ ID NO: 9, and related nucleic acids, vectors, cells, and compositions, as well as method of using same to treat or prevent a disease. IL-1&#x3b2; binding antibodies or IL-1&#x3b2; binding fragments thereof are provided which have desirable affinity and potency.

IL1-&#x3b2; Binding antibodies and fragments thereof

Growing community of inventors

Concord, CA, United States of America

Marina Roell